Protein Degraders (PROTACs & Molecular Glues) Market Surges with Strong 22% CAGR Forecast to 2035

According to the MarketGenics report, the global protein degraders (protacs & molecular glues) market is likely to grow from USD 0.5 Billion in 2025 to USD 3.7 Billion in 2035 at a highest CAGR of ~22% during the time period. The growth of the protein degraders (protacs and molecular glues) market is fueled by the deployment of improved technologies, such as AI-based drug discoveries platforms, machine learning-based target prediction, high-throughput screening, computational modeling, and data-driven molecular optimization tools to improve therapeutic efficacy, speed up drug development, and have precision-targeted degradation of the disease-associated proteins of both pharmaceutical companies and research organizations.

The market of protein degraders (protacs and molecular glues) is reshaped by scientific and technological advancements in the fields of AI-based molecular modeling, cryo-EM structural visualization, and machine learning-based design of degraders to discover and accelerate precision medicine. These innovations are facilitating quicker recognition of ligase substrate couples, enhancing the selectivity of degraders and expanding the pharmacokinetic qualities to achieve better therapeutic results.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Protein Degraders (PROTACs & Molecular Glues) Market Research Report: https://marketgenics.co/press-releases/protein-degraders-protacs-molecular-glues-market-21320

Key Driver, Restraint, and Growth Opportunity Shaping the Global Protein Degraders (PROTACs & Molecular Glues) Market

The market of protein degraders (protacs and molecular glues) is becoming more and more concentrated on the necessity to use personalized and precision therapeutics especially in oncology, neurodegenerative disorders, and rare diseases. The development of biomarker, genomics, and proteomics enable the degraders to be designed to fit the disease profile of a certain individual, which results in greater efficacy and less off-target effects. For instance, in July 2024, MindRank, an AI-empowered clinical-stage drug discovery firm, began an IND-enabling study of its AI-designed molecular glue, MRANK-103, against the MYC signaling pathway.

The protein degraders (protacs and molecular glues) industry is hampered by limited trust and awareness. Consumers and health professionals do not have information on the benefits of PROTACs and molecular glues such as the capability of targeting the hitherto non-druggable proteins and offering targeted treatment choices, which leads to low adoption. A lack of confidence in these therapies also impedes trust. Any misunderstanding of clinical outcome, off-target potential effects or mismatched messaging can further discourage usage. Such struggles are more pronounced in localities that have low levels of scientific literacy, lack access to educational materials and low levels of patient engagement programs. Minimal awareness and consultations delay the penetration and adoption of the market.

To know more about the Protein Degraders (PROTACs & Molecular Glues) Market - Download our Sample Report: https://marketgenics.co/download-report-sample/protein-degraders-protacs-molecular-glues-market-21320

Regional Analysis of Global Protein Degraders (PROTACs & Molecular Glues) Market

The North American market of protein degraders (protacs, molecular glues) occupies the greatest share due to a strong digital health setting, advanced healthcare system, and consumer awareness of preventive well-being. Companies such as U.S. National Institutes of Health (NIH) and Health Canada are involved in promoting research and development of protein degradation therapies by providing grants and funding innovative drug discovery solutions. Moreover, innovative development of AI-based drug discovery systems, target engagement via proteomics, and tailored therapeutic development, government-funded health initiatives, and a mature commercial pharmaceutical industry, are all reinforcers of the North American primacy in the global protein degraders (protacs and molecular glues) market.

Asia-Pacific protein degraders (protacs and molecular glues) market is projected to experience the highest growth rate in the world due to increasing population, growing urbanization and rising healthcare awareness in China, India and Japan amongst others. Cancer, neurodegenerative, and other forms of chronic diseases are becoming increasingly prevalent, and more and more people will be accessing high-quality healthcare infrastructure, increasing demand on specific forms of protein-degradation therapies.

Prominent players operating in the global protein degraders (protacs & molecular glues) market are AbbVie Inc., Amgen Inc., Arvinas, Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb (Celgene), C4 Therapeutics, Inc., Captor Therapeutics S.A., Dialectic Therapeutics, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GSK plc (GlaxoSmithKline), Janssen Pharmaceuticals (Johnson & Johnson), Kymera Therapeutics, Inc., Merck & Co., Inc., Novartis AG, Nurix Therapeutics, Inc., Pfizer Inc., Roche Holding AG (Genentech), Sanofi S.A., Takeda Pharmaceutical Company Limited, Other Key Players.

Buy Now: https://marketgenics.co/buy/protein-degraders-protacs-molecular-glues-market-21320

Recent Development and Strategic Overview:

In February 2024, Neomorph announced a multi-target collaboration with Novo Nordisk to discover novel molecular glue degraders aimed at treating cardiometabolic and rare diseases. The agreement, potentially valued at $1.46 billion, includes upfront and milestone payments, with Neomorph leading discovery and preclinical activities. Novo Nordisk will have exclusive rights to clinical development and commercialization.

In August 2025, Arvinas and Pfizer announced that the U.S. FDA accepted their New Drug Application (NDA) for vepdegestrant (ARV-471), an oral PROTAC estrogen receptor degrader, for the treatment of ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. The NDA is based on data from the Phase 3 VERITAC-2 trial, which demonstrated a significant improvement in progression-free survival compared to fulvestrant.

Get a preview of our Protein Degraders (PROTACs & Molecular Glues) Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/protein-degraders-protacs-molecular-glues-market-21320

Key Trend: Platformization and large-scale partnerships (biology + AI + E3-ligase discovery)

The protein degraders (protacs and molecular glues) market is shifting to consolidated platforms, firms are integrating chemoproteomics, high-throughput E3-ligase ligand discovery, structure-guided design, and AI-driven hit-to-lead workflows into integrated platforms that feed into many programs. This platformization increases the speed of discovery, enhances hit rates of novel E3 ligases, and allows repeating modular workflows to convert degrader discovery into an industrial process. The strategic alliances between platform biotechs (discovery engines) and big pharmas entail clinical development and commercialization of their products, so that portfolios can quickly grow, and risks are distributed.

The growing interests of pharma and biotech companies in the platformization of protein degradation is illustrated by the increasing number of collaborations between AI, advanced biology, and E3 ligase discovery. For instance, in April 2025, Evotec reported major advances in its strategic protein degradation partnership with Bristol Myers Squibb, which triggers US$ 75 million in performance- and program-based milestone payments. Equally, the Gilead Kymera and AbbVie Neomorph alliances represent consolidation around providers of high discovery throughput and chemotype space. Through integrating the design of degraders with AI/ML alongside proteomics-based target engagement, these consortia are enhancing the pace, accuracy, and feedback of the next generation of protein degraders.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.